NUVB

$NUVB Share Price: $6.26 Contract Selected: Jan 15, 2027 $10 Calls Buy Zone: $0.51 – $0.63 Target Zone: $0.85 – $1.04 Potential Upside: 57% ROI Time to Expiration: 178 Days | Updates via https://fxcapta.com/stockinfo/

$NUVB a possibility.......

Nuvation Bio reported updated Phase 2 data for safusidenib in patients with IDH1-mutant Grade 2 glioma, showing a confirmed objective response rate of 52% and a 79% progression-free survival rate at 36 months after nearly 40 months of follow-up in patients who had not received prior chemotherapy or radiation. The median progression-free survival has not yet been reached, and no new safety signals were identified. The company plans to launch a pivotal Phase 3 trial outside the U.S. enrolling approximately 140 patients in regions where vorasidenib is not approved or unavailable, with progression-free survival as the primary endpoint. Nuvation Bio will also initiate a U.S. Phase 2 study enrolling up to 40 patients with IDH1-mutant Grade 2 or 3 glioma whose disease progressed following vorasidenib treatment. $NUVB

@StocktwitsNews “He said the approach positions the company to capture the "whole pie" of the IDH1-mutant glioma market, which RBC estimates could exceed $3 billion in peak sales.” If Varo approved for LGG only valued at $6 B before even it reached $1 B sales in just first year, not peak yet then how do you justify the $3 B peak sales for Safusidenib “ whole pie” theory ? I don’t dislike your $19 PT for 12 months but Safusidenib market is serverly undervalued even in your own theory. No need to hype Safusidenib potentials, Just applies Varo sales as comparable then redo your maths. Of course the risk of FDA approval or CRL should always fact in. Let’s go $NUVB

$NUVB running hot up 9% to 6.33 on 8M+ shares, clearing yesterday's 5.80 close. these vertical breakouts can fade fast once the momentum thins. what level you guys watching here

Nuvation Bio (NYSE: $NUVB ) is leaning into safusidenib’s durability in IDH1‑mutant glioma, with longer‑term Phase 2 data showing deep, sustained responses and an expanded clinical program that now targets both newly diagnosed grade 2 patients and those who progress after vorasidenib. https://prismmarketview.com/companies/nuvation-bio-inc/#news